<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34623592</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-4978</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Molecular biology reports</Title><ISOAbbreviation>Mol Biol Rep</ISOAbbreviation></Journal><ArticleTitle>Influence of GSTP1 rs1695 polymorphism on survival in male patients' amyotrophic lateral sclerosis: a genetic association study in Brazilian population.</ArticleTitle><Pagination><StartPage>1655</StartPage><EndPage>1659</EndPage><MedlinePgn>1655-1659</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11033-021-06724-z</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Glutathione S-transferase Pi (GSTP1) enzyme has a major antioxidant effect on the central nervous system (CNS), where it acts against oxidative damage, an established risk factor for amyotrophic lateral sclerosis (ALS). Hence, the purpose of this study was to evaluate a possible relationship between GSTP1 rs1695 polymorphism and the survival rate of male ALS patients, which is the gender more affected by the disease.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">A case-control study was performed with 56 male ALS patients and 70 healthy male individuals from Midwestern Brazil, which were age-adjusted. GSTP1 rs1695 polymorphism molecular analysis was carried out with restriction fragment length polymorphism. The relationship between ALS patients and GSTP1 rs1695 polymorphism was analyzed using cumulative survival rate as the major outcome, where differences in survival were evaluated through the log-rank test. Our results revealed that mutant genotype (G/G) did not influence the cumulative survival rate of male ALS patients regarding the age of diagnosis (p&#xa0;=&#xa0;0.5) and time from symptom to diagnosis (p&#xa0;=&#xa0;0.3). On the other hand, mutant carriers exhibited a significant survival of fewer than 25 months compared to A/A and A/G genotypes that survive more than 100 months (p&#xa0;=&#xa0;7-E10) in comparison with symptom onset to outcome (p&#xa0;=&#xa0;0.00006).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In summary, our findings revealed that mutant genotype carriers' male patients had a reduced lifetime, which probably may be resulted from oxidative stress exposure in CNS.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Nature B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Sousa Barros</LastName><ForeName>J&#xe9;ssica Barletto</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0002-0377-3004</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Pathology, Department of Biochemistry and Molecular Biology, Institute of Biological Sciences, Federal University of Goi&#xe1;s, Goi&#xe2;nia, Goi&#xe1;s, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Faria Santos</LastName><ForeName>Kamilla</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-0555-3072</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Pathology, Department of Biochemistry and Molecular Biology, Institute of Biological Sciences, Federal University of Goi&#xe1;s, Goi&#xe2;nia, Goi&#xe1;s, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Cruz Pereira Bento</LastName><ForeName>Dhiogo</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-8895-2628</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Pathology, Department of Biochemistry and Molecular Biology, Institute of Biological Sciences, Federal University of Goi&#xe1;s, Goi&#xe2;nia, Goi&#xe1;s, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rehabilitation and Readaptation Medical Center Dr. Henrique Santillo (CRER), Goi&#xe2;nia, Goi&#xe1;s, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prado Assun&#xe7;&#xe3;o</LastName><ForeName>Leandro do</ForeName><Initials>LD</Initials><Identifier Source="ORCID">0000-0002-1743-8151</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Pathology, Department of Biochemistry and Molecular Biology, Institute of Biological Sciences, Federal University of Goi&#xe1;s, Goi&#xe2;nia, Goi&#xe1;s, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>da Silva Santos</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-9480-4362</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Pathology, Department of Biochemistry and Molecular Biology, Institute of Biological Sciences, Federal University of Goi&#xe1;s, Goi&#xe2;nia, Goi&#xe1;s, Brazil. rdssantos@ufg.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>da Silva Reis</LastName><ForeName>Angela Adamski</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0002-8281-7334</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Pathology, Department of Biochemistry and Molecular Biology, Institute of Biological Sciences, Federal University of Goi&#xe1;s, Goi&#xe2;nia, Goi&#xe1;s, Brazil. angela@ufg.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Mol Biol Rep</MedlineTA><NlmUniqueID>0403234</NlmUniqueID><ISSNLinking>0301-4851</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.5.1.18</RegistryNumber><NameOfSubstance UI="C496556">GSTP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.5.1.18</RegistryNumber><NameOfSubstance UI="D051549">Glutathione S-Transferase pi</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051549" MajorTopicYN="N">Glutathione S-Transferase pi</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012150" MajorTopicYN="N">Polymorphism, Restriction Fragment Length</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">GSTP1 rs1695 SNP</Keyword><Keyword MajorTopicYN="N">Genetic polymorphism</Keyword><Keyword MajorTopicYN="N">Oxidative damage</Keyword><Keyword MajorTopicYN="N">Survival rate</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>8</Day><Hour>12</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34623592</ArticleId><ArticleId IdType="doi">10.1007/s11033-021-06724-z</ArticleId><ArticleId IdType="pii">10.1007/s11033-021-06724-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Volont&#xe9; C, Apolloni S, Sabatelli M (2019) Histamine beyond its effects on allergy: potential therapeutic benefits for the treatment of amyotrophic lateral sclerosis (ALS). Pharmacol Ther 202:120&#x2013;131. https://doi.org/10.1016/j.pharmthera.2019.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2019.06.006</ArticleId><ArticleId IdType="pubmed">31233766</ArticleId></ArticleIdList></Reference><Reference><Citation>Riancho J, Bosque-Varela P, Perez-Pereda S et al (2018) The increasing importance of environmental conditions in amyotrophic lateral sclerosis. Int J Biometeorol 62:1361&#x2013;1374. https://doi.org/10.1007/s00484-018-1550-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00484-018-1550-2</ArticleId><ArticleId IdType="pubmed">29713861</ArticleId></ArticleIdList></Reference><Reference><Citation>Eum K-D, Seals RM, Taylor KM et al (2015) Modification of the association between lead exposure and amyotrophic lateral sclerosis by iron and oxidative stress related gene polymorphisms. Amyotroph Lateral Scler Frontotemporal Degener 16:72&#x2013;79. https://doi.org/10.3109/21678421.2014.964259</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.964259</ArticleId><ArticleId IdType="pubmed">25293352</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amico E, Factir-Litvak P, Santella RM, Mitsumoto H (2013) Clinical perspective of oxidative stress in sporadic ALS. Free Radic Biol Med 65:509&#x2013;527. https://doi.org/10.1016/j.freeradbiomed.2013.06.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.06.029</ArticleId><ArticleId IdType="pubmed">23797033</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajewska B, Ka&#x17a;mierczak B, Ku&#x17a;ma-Kozakiewicz M et al (2015) GSTP1 polymorphisms and their association with glutathione transferase and peroxidase activities in patients with motor neuron disease. CNS Neurol Disord Drug Targets 14:1328&#x2013;1333. https://doi.org/10.2174/1871527314666150821104019</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527314666150821104019</ArticleId><ArticleId IdType="pubmed">26295823</ArticleId></ArticleIdList></Reference><Reference><Citation>Ka&#x17a;mierczak B, Ku&#x17a;ma-Kozakiewicz M, Usarek E, Bara&#x144;czyk-Ku&#x17a;ma A (2011) Differences in glutathione S-transferase pi expression in transgenic mice with symptoms of neurodegeneration. Acta Biochim Pol 58:621&#x2013;626. https://doi.org/10.18388/abp.2011_2233</Citation><ArticleIdList><ArticleId IdType="doi">10.18388/abp.2011_2233</ArticleId><ArticleId IdType="pubmed">22132373</ArticleId></ArticleIdList></Reference><Reference><Citation>Zherebtsova AL, Shadrina MI, Levitsky GN et al (2004) Analysis of the glutathione S-transferase P1 gene Ile105Val polymorphism in the patients with sporadic motor neuron disease from Russia. Russ J Genet 40:691&#x2013;693. https://doi.org/10.1023/B:RUGE.0000033319.46071.84</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:RUGE.0000033319.46071.84</ArticleId></ArticleIdList></Reference><Reference><Citation>de Sousa Barros JB, de Faria Santos K, Azevedo RM et al (2021) No association of GSTP1 rs1695 polymorphism with amyotrophic lateral sclerosis: a case&#x2013;control study in the Brazilian population. PLoS ONE 16:1&#x2013;15. https://doi.org/10.1371/journal.pone.0247024</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0247024</ArticleId></ArticleIdList></Reference><Reference><Citation>Little J, Higgins JPT, Ioannidis JPA et al (2009) STrengthening the REporting of Genetic Association studies (STREGA): an extension of the STROBE statement. Genet Epidemiol 33:581&#x2013;598. https://doi.org/10.1002/gepi.20410</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gepi.20410</ArticleId><ArticleId IdType="pubmed">19278015</ArticleId></ArticleIdList></Reference><Reference><Citation>Usarek E, Gajewska B, Ka&#x17a;mierczak B et al (2005) A study of glutathione S-transferase pi expression in central nervous system of subjects with amyotrophic lateral sclerosis using RNA extraction from formalin-fixed, paraffin-embedded material. Neurochem Res 30:1003&#x2013;1007. https://doi.org/10.1007/s11064-005-6771-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-005-6771-1</ArticleId><ArticleId IdType="pubmed">16258849</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku&#x17a;ma M, Jamrozik Z, Bara&#x144;czyk-Ku&#x17a;ma A (2006) Activity and expression of glutathione S-transferase pi in patients with amyotrophic lateral sclerosis. Clin Chim Acta 364:217&#x2013;221. https://doi.org/10.1016/j.cccn.2005.07.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cccn.2005.07.008</ArticleId><ArticleId IdType="pubmed">16109392</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Guennoc AM, Veyrat-Durebex C et al (2012) Amyotrophic lateral sclerosis: a hormonal condition? Amyotroph Lateral Scler 13:585&#x2013;588. https://doi.org/10.3109/17482968.2012.706303</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.706303</ArticleId><ArticleId IdType="pubmed">22873563</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal T, Polanco MJ, Scaramuzzino C et al (2014) Androgens affect muscle, motor neuron, and survival in a mouse model of SOD1-related amyotrophic lateral sclerosis. Neurobiol Aging 35:1929&#x2013;1938. https://doi.org/10.1016/j.neurobiolaging.2014.02.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.02.004</ArticleId><ArticleId IdType="pubmed">24630363</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Henderson RD (2010) Effects of gender in amyotrophic lateral sclerosis. Gend Med 7:557&#x2013;570. https://doi.org/10.1016/j.genm.2010.11.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genm.2010.11.010</ArticleId><ArticleId IdType="pubmed">21195356</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>